SEARCH:   Advanced

Blood, 15 July 2005, Vol. 106, No. 2, pp. 447-453. Prepublished online as a Blood First Edition Paper on January 27, 2005; DOI 10.1182/blood-2004-05-1971. This Article Full Text Full Text (PDF) All Versions of this Article: 2004-05-1971v1 106/2/447    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Testi, A. M. Articles by Mandelli, F. Search for Related Content PubMed PubMed Citation Articles by Testi, A. M. Articles by Mandelli, F. Related Collections Neoplasia Clinical Trials and Observations Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children Anna Maria Testi, Andrea Biondi, Francesco Lo Coco, Maria Luisa Moleti, Fiorina Giona, Marco Vignetti, Giuseppe Menna, Franco Locatelli, Andrea Pession, Elena Barisone, Giulio De Rossi, Daniela Diverio, Concetta Micalizzi, Maurizio Aricò, Giuseppe Basso, Robert Foa, and Franco Mandelli From the Dipartimento di Biotecnologie Cellulari ed Ematologia, Università "La Sapienza," Rome; the Dipartimento di Biopatologia e Diagnostica per Immagini, Università "Tor Vergata," Roma; Clinica Pediatrica, Ospedale Nuovo "San Gerardo," Monza; the Divisione Pediatria Ematologia, Ospedale Pausilipon, Napoli; Oncoematologia Pediatrica, IRCCS Policlinico San Matteo, Pavia; the Dipartimento di Pediatria, Università di Bologna,; the Dipartimento Scienze Pediatriche Adolescenza, Università di Torino; Divisione di Ematologia Pediatrica, Ospedale Bambin Gesú, Roma; the Dipartimento di Ematologia-Oncologia, Istituto Giannina Gaslini, Genova; Oncoematologia Pediatrica, Ospedale dei Bambini, Palermo; and Clinica Pediatrica, Università di Padova; Italy. The role of all-trans retinoic acid (ATRA) in pediatric acute promyelocytic leukemia (APL) is the topic of several ongoing studies. The results of the Italian pediatric experience with the multicentric Gruppo Italiano per le Malattie Ematologiche dell'Adulto (GIMEMA)–Italian Pediatric Hematology and Oncology Group (AIEOP) "AIDA" (ATRA and idarubicin) trial are presented. Of the 983 patients with APL enrolled in this protocol between January 1993 and June 2000, 124 (13%) had younger than 18 years. Treatment consisted of ATRA and idarubicin induction followed by 3 polychemotherapy consolidation courses. Molecular response by reverse transcriptase–polymerase chain reaction (RT-PCR) was assessed after consolidation and patients who were PCR– were randomized for different maintenances. One hundred and seven children were eligible and evaluable for induction: 103 (96%) achieved a hematologically complete remission. Overt ATRA syndrome was observed in 2 patients and pseudotumor cerebri was observed in 10 patients. Ninety-four patients were evaluable for RT-PCR analysis at the end of consolidation: 91 (97%) proved PCR+ and 3 PCR–. The overall survival and event-free survival (EFS) are 89% (95% confidence interval [c.i.]: 83%-95%) and 76% (c.i.: 65%-85%), respectively, at more than 10 years. A white blood cell (WBC) count at diagnosis of greater than 10 x 109/L had a significant impact on EFS (59% vs 83% at 10 years). These results highlight the efficacy and feasibility of the AIDA protocol in the pediatric APL population. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: APL treatment Italian style: is this the cure? James Feusner Blood 2005 106: 392-393. [Full Text] [PDF] This article has been cited by other articles: Z.-Y. Wang and Z. Chen Acute promyelocytic leukemia: from highly fatal to highly curable Blood, March 1, 2008; 111(5): 2505 - 2515. [Abstract] [Full Text] [PDF] G. J.L. Kaspers and C. M. Zwaan Pediatric acute myeloid leukemia: towards high-quality cure of all patients Haematologica, November 1, 2007; 92(11): 1519 - 1532. [Abstract] [Full Text] [PDF] P. Niscola, C. Romani, L. Cupelli, L. Scaramucci, A. Tendas, T. Dentamaro, S. Amadori, and P. de Fabritiis Mucositis in patients with hematologic malignancies: an overview Haematologica, February 1, 2007; 92(2): 222 - 231. [Abstract] [Full Text] [PDF] D. Montagna, R. Maccario, F. Locatelli, E. Montini, S. Pagani, F. Bonetti, L. Daudt, I. Turin, D. Lisini, C. Garavaglia, et al. Emergence of antitumor cytolytic T cells is associated with maintenance of hematologic remission in children with acute myeloid leukemia Blood, December 1, 2006; 108(12): 3843 - 3850. [Abstract] [Full Text] [PDF] M. A. Sanz, M. S. Tallman, and F. Lo-Coco Practice Points, Consensus, and Controversial Issues in the Management of Patients with Newly Diagnosed Acute Promyelocytic Leukemia Oncologist, November 1, 2005; 10(10): 806 - 814. [Abstract] [Full Text] [PDF] J. J. Ortega, L. Madero, G. Martin, A. Verdeguer, P. Garcia, R. Parody, J. Fuster, A. Molines, A. Novo, G. Deben, et al. Treatment With All-Trans Retinoic Acid and Anthracycline Monochemotherapy for Children With Acute Promyelocytic Leukemia: A Multicenter Study by the PETHEMA Group J. Clin. Oncol., October 20, 2005; 23(30): 7632 - 7640. [Abstract] [Full Text] [PDF] M. A. Sanz, M. S. Tallman, and F. Lo-Coco Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia Blood, April 15, 2005; 105(8): 3019 - 3025. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020